Previous close | 3.4000 |
Open | 3.4300 |
Bid | 3.3700 x 100 |
Ask | 3.4200 x 200 |
Day's range | 3.3700 - 3.6500 |
52-week range | 1.2500 - 4.6500 |
Volume | |
Avg. volume | 322,780 |
Market cap | 256.804M |
Beta (5Y monthly) | 1.99 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
LOS ANGELES, April 24, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
LOS ANGELES, April 23, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship product, Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Sprouts Farmers Market, marking its inaugural major grocery debut. As one of the fastest-growing retailers in the United States, Sprouts Farmers Market now offers Tru Niagen to its health-conscious consumers i
LOS ANGELES, March 26, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program by Alkemist Labs, a leading third-party testing laboratory known for its rigorous herbal and dietary supplement analysis. As the number one NAD+ supplement company in the US†, Tru Niagen features NIAGEN